A Study to Test How SB756050 Affects Subjects With Type 2 Diabetes Mellitus After 6 Days of Dosing.
Status:
Completed
Trial end date:
2009-03-03
Target enrollment:
Participant gender:
Summary
This is an escalating dose study in subjects with T2DM, which will consist of four
overlapping cohorts receiving 6 days of SB756050 to assess safety, pharmacokinetics, and
pharmacodynamics.